

## Recombinant SARS-Cov-2 (Omicron, B.1.1.529) Spike trimer protein, C-His (HEK293)

Catalog Number: bs-43077P

Concentration: >0.5 mg/ml

AA Seq: 16-1213/1273

Predicted MW: 137

Detected MW: 150-180 kDa

Tags: C-His

Activity: Not tested

Endotoxin: Not analyzed

Purity: >90% as determined by SDS-PAGE

Purification: AC

Form: Lyophilized or Liquid

Storage: PBS (pH7.4).


Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

**Background:** The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.


### VALIDATION IMAGES



The purity of the protein is greater than 90% as determined by reducing SDS-PAGE.



Measured by its binding ability in a functional ELISA. Immobilized human ACE2, His-Avi Tag (Cat: bs-46001P) at 2µg/mL (100 µL/Well) can bind SARS-CoV-2 Spike trimer Protein (His Tag) (Omicron/B.1.1.529) (Cat: bs-43077P), the EC50 is 1.5µg/mL.



Measured by its binding ability in a indirect ELISA. Immobilized SARS-CoV-2 Spike trimer Protein (His Tag) (Omicron/B.1.1.529) (Cat: bs-43077P) at 2µg/mL (100 µL/Well) can bind Anti-SARS-CoV-2 Spike Monoclonal antibody (Cat:bsm-41622M&bsm-41476M&bsm-41630M).